AI in Drug Development is Not a Data Problem — It’s An Evidence Problem
Drug development isn’t limited by the amount of data we collect, but by our ability…
AI in Drug Development is Not a Data Problem — It’s An Evidence Problem
Drug development isn’t limited by the amount of data we collect, but by our ability to preserve the context, meaning and relationships that transform data into evidence. The post AI in Drug Development is Not a Data Problem — It’s An Evidence Problem appeared first on MedCity News.
How to Keep Clinicians Satisfied, the Ascension Way
Ascension is pushing AI beyond note-taking to tackle the billing, order entry and nursing handoff work still weighing on clinicians after a patient visit ends. The post How to Keep Clinicians Satisfied, the Ascension Way appeared first on MedCity News.
Compliance Alone Won’t Fix the Home Health Fraud Problem
[Sponsored] With home health fraud growing more sophisticated through AI, post-pay audits are no longer enough. Payers must shift to proactive, tech-driven prevention to catch improper claims before paying them. The post Compliance Alone Won’t Fix the Home Health Fraud Problem appeared first on MedCity News.
Many States Cover Doula Care, but Access to a ‘Birthing Bestie’ Is Often Out of Reach
Doula Taja Iglesias and her business partner have built a space in Alexandria, Virginia, that’s all things pregnancy, birth, and childcare. Comfortable couches in one area invite expectant parents to settle in for birth education classes. In another, a colorful pile of toys await the babies and toddlers. And there’s a free supply of diapers…
Same Knee Surgery, Twice the Price: Hospital Monopolies Push Up Healthcare Costs
More than a million times a year, a U.S. surgeon slices open a knee, strips out worn cartilage, caps the leg bones with metal, and drops in a plastic spacer to allow the new joint to glide. While knee replacement procedures have become standard, however, the prices charged have not. At Catawba Valley Medical Center…
Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs
In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s total haul to nearly $440 million. Braveheart’s lead drug could be competitive with a blockbuster Bristol Myers Squibb medicine for a type of cardiomyopathy. The post Braveheart Bio’s $382M IPO…
MedCity FemFwd: Employer Strategies for Women’s Health
In this episode, we’re joined by Cheryl Larson, president and CEO of the Midwest Business Group on Health, for our first in-person recording at MedCity News’ recent Bullseye event. The post MedCity FemFwd: Employer Strategies for Women’s Health appeared first on MedCity News.
Two Differing POVs Emerge About the Hinge-Cylinder Deal
Hinge Health’s acquisition of Cylinder expands it into GI care, but experts differ on whether employers will favor convenience or specialized solutions. The post Two Differing POVs Emerge About the Hinge-Cylinder Deal appeared first on MedCity News.
Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs
Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted on the Nasdaq, raising cash for cancer drugs designed to address mutations not covered by currently available therapies. The post Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain…
Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs
The problem may not be the investment. It may be the target of the intervention. The post Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs appeared first on MedCity News.
